Insmed (NASDAQ:INSM) Insider Sells $666,982.03 in Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 6,149 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $108.47, for a total transaction of $666,982.03. Following the transaction, the insider owned 41,613 shares of the company’s stock, valued at $4,513,762.11. This represents a 12.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Alexander Smith also recently made the following trade(s):

• On Monday, March 30th, Michael Alexander Smith sold 19,638 shares of Insmed stock. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24.

Insmed Stock Performance

Insmed stock opened at $106.24 on Monday. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The firm has a 50-day moving average price of $137.89 and a two-hundred day moving average price of $160.69. The firm has a market capitalization of $23.03 billion, a price-to-earnings ratio of -18.48 and a beta of 0.89. Insmed, Inc. has a 52-week low of $65.56 and a 52-week high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.14. The company had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. Insmed’s revenue was up 229.7% compared to the same quarter last year. During the same quarter last year, the business earned ($1.42) earnings per share. Sell-side analysts expect that Insmed, Inc. will post -2.52 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Raymond James Financial assumed coverage on Insmed in a research report on Friday, April 10th. They issued an “outperform” rating and a $200.00 target price on the stock. Leerink Partners increased their price target on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 24th. Jefferies Financial Group assumed coverage on Insmed in a report on Monday, March 16th. They set a “buy” rating and a $228.00 price target on the stock. Wells Fargo & Company cut their price objective on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Bank of America upped their price objective on shares of Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $210.95.

Institutional Investors Weigh In On Insmed

Institutional investors have recently added to or reduced their stakes in the company. CoreCap Advisors LLC acquired a new position in shares of Insmed during the 4th quarter valued at $27,000. Reflection Asset Management bought a new stake in shares of Insmed in the 4th quarter worth $30,000. GraniteShares Advisors LLC acquired a new stake in shares of Insmed in the fourth quarter valued at $30,000. CIBC Private Wealth Group LLC boosted its stake in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new position in Insmed during the fourth quarter valued at about $32,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.